Welcome to our dedicated page for Aptorum Group SEC filings (Ticker: APM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aptorum Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aptorum Group's regulatory disclosures and financial reporting.
Aptorum Group Limited filed a post-effective amendment to register up to 2,060,000 Class A Ordinary Shares issuable upon exercise of warrants (the “2025 Warrants”), including 2,000,000 Investor Warrants at an original exercise price of $2.00 and 60,000 Placement Agent Warrants at $2.50. The prospectus registers resale by the selling securityholders; the Company will not receive proceeds from resale but will receive cash exercise proceeds when warrants are exercised for cash. The filing discloses risks tied to the Company’s Hong Kong operations, PRC regulatory uncertainty including the CSRC Trial Measures and HFCAA/PCAOB inspection risks, and summarizes the pending DiamiR merger and related governance, consideration and conditionality.
Aptorum Group plans to issue 19,917,413 shares of Aptorum Delaware common stock to DiamiR Biosciences stockholders as consideration in a planned merger. Existing Aptorum holders would receive 9,536,034 common shares and 1,796,934 non‑voting Series A preferred shares upon a redomiciling to Delaware. After closing, DiamiR investors are expected to own about 70% of the combined company and current Aptorum shareholders about 30%. Aptorum will deregister from the Cayman Islands, domesticate in Delaware, consolidate its shares at a 2‑for‑1 to 10‑for‑1 ratio, adopt a 4,500,000‑share incentive plan, and rename the combined business Niki BioSolutions, Inc., with stock expected to trade on Nasdaq under the symbol “NIKI.”
Aptorum Group Limited files a Pre-Effective Amendment No. 3 to a Form S-4 registering securities in connection with a proposed merger with DiamiR Biosciences Corp. The filing describes a domestication from the Cayman Islands to Delaware, a Merger under a July 14, 2025 Merger Agreement, and related shareholder action items to be voted at a Special Meeting.
The proxy/prospectus discloses the proposed exchange mechanics (a Conversion Ratio formula), pro forma ownership (DiamiR ~70% and Aptorum ~30% immediately after closing), an example issuance of 9,536,034 Aptorum Delaware common shares and 1,796,934 Series A preferred shares to current Aptorum holders if issued on April 30, 2026, and an illustrative issuance of 19,917,413 Aptorum Delaware common shares to DiamiR stockholders. The filing describes contractual interim payments: a management services fee increased to $105,000 per month and an IP license upfront payment of $5,000 plus monthly $1,200.
Aptorum Group Limited files a Form S-4 pre-effective amendment registering 19,917,413 shares of Aptorum Delaware common stock for issuance to DiamiR Biosciences stockholders in a planned merger. Existing Aptorum holders would receive 9,536,034 common shares and 1,796,934 Series A preferred shares upon domestication to Delaware.
After the merger, DiamiR and current Aptorum shareholders are expected to own about 70% and 30% of the combined company, which plans to be renamed Niki BioSolutions, Inc. and trade on Nasdaq as “NIKI.” Proposals include a reverse stock split, Cayman-to-Delaware domestication, a new 2025 incentive plan, and board reconstitution.
CEO Ian Huen controls roughly 86.7% of voting power and has agreed to vote in favor of all proposals, effectively assuring approval. The filing also details Hong Kong/PRC regulatory and HFCAA-related audit risks, cash transfers to subsidiaries, and management and IP agreements with DiamiR extended to June 30, 2026.
Aptorum Group Limited (APM) files a Pre-Effective Amendment to a Form S-4 to register shares in connection with its proposed merger with DiamiR Biosciences Corp. Under the Merger Agreement, the surviving public company will domesticate to Delaware and be renamed Niki BioSolutions, Inc.
The transaction contemplates a post-closing ownership mix of approximately 70% for DiamiR stockholders and 30% for existing Aptorum shareholders. The proxy seeks shareholder approvals for a share consolidation, Domestication, issuance of shares exceeding 20% of outstanding common stock to DiamiR stockholders, a new equity incentive plan, director appointments and related matters. Major holder Jurchen Investment Corporation (controlled by CEO Ian Huen) holds voting power of ~86.71%, and has entered into a voting agreement in support of the proposals.
Aptorum Group Limited, a Cayman Islands-based biopharma company listed on the Nasdaq Capital Market, files its annual report describing a clinical‑stage business with no revenue from product sales and a heavy reliance on raising additional capital to fund operations.
The company highlights extensive risks around its preclinical and clinical drug pipeline, regulatory approvals, intellectual property protection, dependence on third parties, and operating exposure to Hong Kong and PRC regulatory regimes. Its auditor has expressed substantial doubt about Aptorum’s ability to continue as a going concern, and the company also warns about potential Nasdaq delisting, PCAOB inspection issues, and concentrated voting control through Class B shares.
Aptorum Group Limited amended its previously reported merger plans with DiamiR Biosciences Corp. by extending key dates. The termination date for their planned merger, originally set at December 31, 2025, has been moved to June 30, 2026 as the parties continue working to satisfy closing conditions.
The related Management Services Agreement and Intellectual Property License Agreement have also been extended to June 30, 2026, with an amendment to the Management Services Agreement filed as an exhibit. Aptorum has filed a Form S-4 registration statement and plans to mail shareholder meeting notices so its shareholders can vote on approving the proposed transactions.
Aptorum Group Limited reported the results of its 2025 annual meeting of shareholders held on March 10, 2026. A total of 2,521,856 shares, representing 96.97% of the voting power entitled to vote, were present by proxy, establishing a strong quorum.
Shareholders voted on two proposals. For director elections, 180,344,392 votes were cast for Justin Wu, with 73,930 abstain/withheld, and 180,344,410 votes were cast for Douglas Arner, with 73,912 abstain/withheld. The second proposal received 180,394,457 votes for, 23,096 against and 769 abstentions, with no broker non-votes reported.
Aptorum Group Limited reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price requirement of $1 per share under Listing Rule 5550(a)(2). The notice does not immediately affect the listing or trading of Aptorum’s shares.
The company has a 180-calendar-day grace period, until September 1, 2026, to regain compliance. During this time, Aptorum plans to evaluate options to restore compliance, including a potential reverse stock split, and states it is committed to maintaining its Nasdaq listing.